4%) and 216 CD (266%) EIMs were observed in 329 (406%) patient

4%) and 216 CD (26.6%). EIMs were observed in 329 (40.6%) patients, 210 UC (35.3%) and 119 CD (55.1%) (p < 0.0001). 37 EIMs were observed before the diagnosis of IBD (11.2%), 229 EIMs after diagnosis (69.6%) and 63 (19.2%) were present at the time of diagnosis. The EIMs found were: 240 musculoskeletal (29.6%); 47 mucocutaneous (5.8%); 26 ocular (3.2%); 6 hepatobiliary (0.8%) and 10 endocrinological (1.2%). Musculoskeletal manifestations were found in 71 CD and in 169 UC (p < 0.0001). In particular, arthritis Type 1 were found in 41 CD (19%) and in 61 UC (10.2%) (p = 0.0012) and arthritis Type 2 in

25 CD (11.6%) and in 100 UC (16.8%) (p = 0.0012). Mucocutaneous CP-673451 manifestations were observed in 26 CD patients and in 21 UC patients (p = 0.0049). Ocular manifestations were observed in 16 CD (7.4%) and in 10 UC (1.7%), (p = 0.0093). Hepatobiliary

manifestations were found in 2 CD (0.9%) and in 4 UC (0.7%) (p = 1.0) and endocrinological in 3 CD (1.4%) and in 7 UC (1.2%), (p = 1.0). Conclusion: EIMs were significantly more frequent in CD than in UC, in particular mucocutaneous, arthritis Type 1 and uveitis. Key Word(s): 1. EIMs; 2. IBD; 3. ULCERATIVE COLITIS; 4. CROHN’S DISEASE; Presenting Author: VISHAL SHARMA Additional Authors: RANJIT SREERAMA, SURINDERS RANA, RAVI SHARMA, CHALAPATHI RAO, RITAMBHRA NADA, RAJESH GUPTA, LILESHWAR KAMAN, Galunisertib cell line KARTAR SINGH, DEEPAKK BHASIN Corresponding Author: DEEPAKK BHASIN Affiliations: PGIMER Objective: Subset of patients with Ulcerative colitis needs immunomodulators for maintaining the disease in remission. The factors at presentation that can predict the need for immunomodulators

have not been adequately studied especially in the MCE Indian population. Methods: We studied 81 patients (males 40; mean age 38.69 ± 12.90 yrs) with UC (41 prospectively & 40 retrospectively) and noted clinical presentation, duration, extra-intestinal features, extent of disease, haematological and biochemical features, and histology of the endoscopic biopsy specimens. We compared these features amongst patients who required immunomodulators and those who did not. Results: The presenting symptoms were blood in stools (100%), mucus in stools (98.8%), abdominal pain (35.8%), anorectal pain (14.8%) and extra intestinal features (4.9%). Seven patients underwent colectomy and two patients died during the study period. Immunomodulators were used in 19 patients (Azathiopurine 16, mycophenolate mofetil 2, Tacrolimus 1) and the remaining patients were in remission with 5-amino salicyclic acid (5-ASA analogues). On comparison of patients needing immunomodulators with patients maintaining remission on 5-ASA we found that the two groups were similar in age (38.68 ± 10.6 and 38.69 ± 13.6), gender (male; 47.3 and 59%), and clinical features as well as the blood investigations. But the patients who received immunomodulators were more likely to have pancolitis (47.4% versus 16.1%, p = 0.005).

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>